BACKGROUND: Studies of obesity and survival among patients with breast cancer produce conflicting results, possibly because of heterogeneity by molecular subtype. METHODS: This study examined whether the association of body mass index (BMI) at diagnosis with breast cancer recurrence and survival varied across subtypes defined by PAM50 (Prediction Analysis of Microarray 50) gene expression. Included were 1559 Kaiser Permanente Northern California members ages 18 to 79 years who had PAM50 assays and were diagnosed with American Joint Committee on Cancer stage I through III breast cancer from 1996 to 2013. Patients reported weight and height. Cox regression models were adjusted for age, menopause, race/ethnicity, stage, and chemotherapy. RESULTS: Over a median of 9 years (maximum, 19 years), 378 women developed recurrent disease, and 312 died from breast cancer. Overall, BMI was not associated with breast cancer recurrence or survival when controlling for subtype (eg, the hazard ratio per 5 kg/m 2 of BMI was 1.05
INTRODUCTION
Although prediagnosis obesity is an established risk factor for postmenopausal breast cancer, studies of obesity and breast cancer survival have produced heterogeneous results. 1, 2 Potential reasons for these inconsistencies include methodological differences (eg, exposure timing, control for confounding by physical activity or comorbidities, etc). 1 In addition, there may be threshold effects: associations are often strongest for (or do not emerge until) a body mass index (BMI) 35 kg/ m 2 is reached. [3] [4] [5] [6] Yet another consideration is that breast cancer is typically treated as a single disease, ignoring the biologic diversity in tumor characteristics that influence outcomes like recurrence and breast cancer death. 7 The limited research within subtypes suggests heterogeneity in the influence of obesity on breast cancer outcomes, with obesity often appearing detrimental only for select subtypes. 4, [8] [9] [10] [11] [12] [13] [14] [15] [16] This raises the possibility that certain subtypes may be more responsive to lifestyle intervention. To shed light on the biologic pathways through which obesity influences breast cancer outcomes, accurate classification of subtypes is essential.
Gene expression profiling, which is the gold standard for intrinsic subtyping, improves prognostication and predicts therapeutic response better than clinicopathologic subtypes. [17] [18] [19] Without gene expression data, researchers often assign subtypes from estrogen receptor (ER) and progesterone receptor (PR) status and/or from human epidermal growth factor receptor 2 (Her2), proliferation markers, or tumor grade. These subtypes do not always align with intrinsic subtypes classified by gene expression-based assays. [17] [18] [19] PAM50 (Prediction Analysis of Microarray 50) subtyping more accurately characterizes the spectrum of breast cancer biology and is more prognostic for outcome than immunohistochemistry (IHC) methods. 19 Previously, we applied the PAM50 assay to archived tumor tissue from the Life After Cancer Epidemiology (LACE) and Pathways studies; the PAM50 assay is a real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) subtyping classifier that measures the expression of 50 genes representative of 5 breast cancer intrinsic subtypes. 17, 20 To our knowledge, this is the largest study to evaluate the association of BMI and breast cancer outcomes within PAM50 subtypes 16 and the first to control for confounders or examine whether comorbidities, physical activity, or disease characteristics explain the association of BMI with breast cancer outcomes within subtypes. Understanding whether BMI influences breast cancer survival within accurately classified subtypes could inform a precision medicine approach that tailors lifestyle recommendations to the molecular characteristics of an individual patient's tumor.
MATERIALS AND METHODS

Study Overview
We included patients who had American Joint Committee on Cancer stage I through III breast cancer from a population-based, prospective cohort at Kaiser Permanente Northern California (KPNC) composed of the LACE 21 and Pathways 22 studies. Women from the LACE study were ages 18 to 79 years at diagnosis (1996) (1997) (1998) (1999) (2000) and had completed chemotherapy by enrollment (<39 months postdiagnosis; on average, 23 months from diagnosis to enrollment). Women from the Pathways study were aged 21 years at diagnosis (2005-2013) and had enrolled on average 2 months postdiagnosis.
Women were followed until June 30, 2015, and were censored at the date of recurrence or death, which was ascertained by combining self-report, the electronic medical record, and KPNC mortality files. Outcomes were verified by medical record review. Cause of death was ascertained from death certificates. Participants provided informed consent, and KPNC institutional review boards approved the protocols.
Classification of Intrinsic Subtypes by PAM50 Gene Expression
In total, 1691 tumors from 6641 enrolled patients underwent PAM50 molecular subtyping using a stratified casecohort study design. ER, PR, and Her2 status (determined by IHC and fluorescence in situ hybridization [for Her2]) defined the sampling strata. All ER-negative and PR-negative or Her2-positive tumors were sampled as well as a random 18% sample of common phenotypes (ER-positive or PR-positive and Her2-negative) 17, 18 ; characteristics of the stratified random sample and the process of conducting the assays have been published elsewhere. 17, 18, 20 In brief, qRT-PCR was conducted for 50 target genes comprising the PAM50 intrinsic subtype classified by laboratory personnel who were blinded to patient information. Applying centroid-based algorithms to the calibrated log-expression ratio for the 50 genes in the PAM50 assay resulted in 5 continuous-scale, normalized subtype scores representing the degree of Spearman correlation of gene expression with that of prototype luminal A, luminal B, basal-like, and Her2-overexpressing (Her2-E) breast tumors. The subtype with the highest score became the predicted intrinsic subtype for that case. Compared with IHC classification, PAM50 subtyping distinguishes between luminal A and B (ER-positive) tumors and more accurately classifies basal-like and Her2-E tumors. Results from the Spanish Breast Cancer Research Group GEICAM-9906 trial indicate that, as part of this more accurate characterization of breast cancer biology, nearly one-third of tumors classified as triplenegative by IHC were classified as Her2-E by PAM50; approximately two-thirds of clinically Her2-positive samples are classified as Her2-E subtype by PAM50, and the remaining classified as luminal B. Luminal B tumors are mainly distinguished from luminal A as more proliferative and less frequently PR-positive. 19 
BMI and Covariates
On enrollment questionnaires, women from the LACE study reported current height and recalled weight 1 year before diagnosis. Women from the Pathways study reported current height and weight at enrollment (<7 months after diagnosis). Measured heights and weights were first electronically recorded in 2005; thus, selfreported measures were used for "at-diagnosis" BMI. Women reported race/ethnicity and moderate/vigorous recreational physical activity in the preceding 6 months. 23 Patient age, stage, comorbidities in the Charlson index, 24 menopausal status, and treatment information (receipt of adjuvant/neoadjuvant chemotherapy and hormone or radiation therapy) were obtained from questionnaires, the electronic medical record, and the KPNC Cancer Registry.
Original Article
Statistical Analysis
We excluded women who had missing PAM50 or IHC data (n 5 56), normal-like subtypes (n 5 52), missing BMI (n 5 11), and a BMI <18.5 kg/m 2 (n 5 13), leaving a total of 1559 women. Analyses were weighted to account for the stratified sampling design for unbiased estimation of population parameters and standard errors. 25, 26 We computed the cumulative incidence of death from breast cancer according to BMI at diagnosis (Fig. 1) . Descriptive statistics used the "surveymeans" procedure in SAS 9.3 (SAS Institute Inc, Cary, NC). We used Cox proportional hazards regression accounting for delays between diagnosis and cohort entry (0-3 years postdiagnosis) to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for continuous BMI ( 2 ) with recurrence and breast cancer-specific death.
We examined associations controlling for PAM50 subtype, then stratified analyses by subtype. 17 Models adjusted for potential confounders that were selected a priori based on previous literature: age (<50 years, 50 to < 60 years, 60 to < 70 years, or 70 years), menopausal status, race/ethnicity (non-Hispanic white, Asian/Pacific Islander, Hispanic/Latina, or black/African American), study, stage, and any receipt of chemotherapy. Because adjustment for radiation and hormone therapy did not alter the associations, they were excluded from the models. Because of limited power and common pathways (eg, endogenous estrogen), 27 we grouped luminal versus nonluminal breast cancers in sensitivity analyses. To explore mediators, we controlled for physical activity and comorbidities at diagnosis in secondary analyses. Table 1 lists characteristics by BMI category accounting for sampling weights. Most women had stage I (50%) or II (43%) breast cancer; 562 (54%) had luminal A, 345 (20%) had luminal B, 342 (15%) had Her2-E, and 310 (11%) had basal-like subtypes. The mean 6 standard deviation BMI was 28 6 8 kg/m 2 , and the mean 6 standard deviation age was 58 6 15 years. Compared with normalweight women, women who had class II/III obesity were more likely to have comorbidities and stage II/III cancer and were less likely to exercise or to be non-Hispanic white. Of note, the stage distribution within BMI categories differed by subtype: among the luminal breast cancers, a smaller proportion of obese (vs nonobese) women had stage I disease (46% vs 54%); this pattern was less apparent among women with nonluminal breast cancers, 40% of whom had stage I disease regardless of obesity.
RESULTS
During a median follow-up of 9-years (maximum, 19 years), there were 378 recurrences and 544 deaths, including 312 deaths from breast cancer. Figure 1 illustrates the incidence of breast cancer-specific death by BMI category. The dose response was clearest for luminal A cancers, where breast cancer deaths increased with increasing BMI. There was a suggestion of an elevated risk with class I obesity among luminal B subtypes but no indication of any increased risk with increasing BMI for Her2-E or basal-like subtypes.
When all breast cancers were examined together with adjustment for subtype, BMI had no association with recurrence or breast cancer death ( ). There was no apparent correlation between higher BMI and breast cancer outcomes among nonluminal subtypes (HR, 0.90; 95% CI, 0.71-1.14). Additional adjustment for the explanatory variablescomorbidities and moderate/vigorous physical activitydid not alter the results (Supporting Table 2 ; see online supporting information). DISCUSSION This is the largest prospective cohort to examine BMI and breast cancer outcomes separately by PAM50 subtype and the first to do so adjusting for confounders. Among women with luminal A subtypes, class II/III obesity at diagnosis doubled the risk of breast cancer death. However, there was no significant association for overweight or mild obesity or for other tumor subtypes. One prior study with PAM50 gene expression assays examined BMI 16 and did not adjust for any covariates when reporting associations by subtype: consistent with our results, Ligibel et al observed no significant associations with BMI among luminal B, basal-like, or HER2-E subtypes. 16 The unadjusted HR for recurrence-free survival in luminal A cancers was 1.23 (95% CI, 1.08-1.40) per 5-kg/m 2 in their report, very close to the unadjusted HR of 1.24 (95% CI, 1.06-1.46) in our study (see Table 2 for the multivariable- adjusted HR). These studies demonstrate that stratifying tumors into biologically homogenous categories identifies patients whose cancer outcomes are influenced by obesity (luminal). One hypothesized mechanism linking obesity to breast cancer outcomes is increased endogenous estrogen. 2, 27 Supporting the importance of estrogen, prospective cohort studies indicate that postmenopausal obesity increases the risk of invasive breast cancer for ER-positive/ PR-positive (not ER-negative/PR-negative) tumors, particularly among women who do not receive postmenopausal hormone therapy. [28] [29] [30] [31] The limited data examining BMI within IHC subtypes often identifies obesity as a prognostic factor for ER-positive/PR-positive tumors only. 10 Although increased endogenous estrogen could fuel the growth of ER-positive tumors, in our study, BMI was only associated with breast cancer outcomes among luminal A subtypes: there was no statistically significantly increased risk in luminal B subtypes, which are also ER-positive, although to a lesser extent. 32 However, stratifying by luminal versus nonluminal tumors (Fig. 2) , the risk of breast cancer death increased with increasing BMI among luminal cancers. This is consistent with an estrogen mechanism.
Additional hypotheses for how obesity influences prognosis include diagnosis at later stages and inflammation and insulin resistance, which contribute to disease progression. 2, 27 Indeed, obese women with luminal breast cancers tended to have later stage at diagnosis, which could indicate later detection (eg, noncompliance with recommended screenings) or faster growing tumors.
However, the association of higher BMI with adverse outcomes in luminal breast cancer remained after adjustment for stage ( Table 2 ), suggesting that stage does not explain the correlation. Adjustment for physical activity or comorbidities at diagnosis (including diabetes) also did not alter the conclusions (Supporting Table 2 ; see online supporting information). Although physical activity and comorbidities are related to inflammation and insulin resistance, they are not direct measurements: systemic, lowgrade inflammation may still be a major pathway through which obesity influences outcomes in women with luminal A breast cancer.
Another potential explanation for our findings is that aggressive tumor subtypes operate through faster acting pathways that are weakly related to BMI: aggressive subtypes like luminal B, Basal-like, and Her2-E have a high risk of early recurrence (<5 years), 17 and the underlying biology of these highly proliferative tumors may not be readily modifiable. Meanwhile, luminal A cancers have a higher risk of late recurrence (>5 years), 17 and BMI may more readily effect tumor growth through estrogen and other pathways in these more indolent cancers. Of note, even in ER-positive tumors with a good prognosis, greater proliferation markers distinguish those at risk of late recurrence. 33 A prior study in our PAM50 cohort indicated that class II obesity was associated with a higher proliferation score, 20 suggesting that, even within a given subtype, obese women have more proliferative tumors and thus greater a probability of recurrence/death. This hypothesis is consistent with our observation that, among women with luminal A tumors, the cumulative incidence curves for breast cancer death diverged around 5 years postdiagnosis (Fig. 1B) , with obese women assuming the highest risk. Furthermore, a study examining ER-positive breast cancers indicated that class II/III obesity was associated with an increased risk of late recurrence (class II obesity: HR, 1.40; 95% CI, 1.05-1.86; class III obesity: HR, 1.41; 95% CI, 1.02-1.93). 4 Although it is possible that cumulative exposure to adiposity over a woman's lifetime defines tumor characteristics and thus its effects on breast cancer outcomes are not modifiable, it is also possible that, for slower growing tumors (eg, luminal A), the BMI at diagnosis influences tumor progression. 27 The lack of a significant association of BMI with cancer outcomes among more aggressive subtypes raises the question of whether lifestyle interventions will be equally effective for these patients, a question that could not be answered by examining a BMI at a single time point as in our study. Although an ongoing, randomized, controlled trial of weight loss among overweight/obese breast cancer survivors 2 ) and breast cancer-specific survival are illustrated among women with luminal and nonluminal breast cancers (n 5 1559). Hazard ratios and confidence intervals are weighted to account for the stratified case-cohort study design, with strata defined according to immunohistochemical clinical subtype and adjusted for age, menopausal status, race/ethnicity, study, disease stage, and chemotherapy.
may partially answer this question, the trial excludes Her2-positive cancers. 34 An alternative approach would be to tailor lifestyle interventions for those patients most likely to derive benefit. Supporting the potential of a precision oncology approach targeted by tumor subtype, a previous study in our cohort indicated that luminal A cancers were preferentially responsive to exercise. 35 These results provide additional support for the idea that the impact of obesity and obesityrelated behaviors on breast cancer outcomes could differ according to the molecular features of the tumor.
A limitation of the current study is that BMI does not distinguish lean from fat mass nor describe fat distribution; this is especially true among older adults with chronic diseases. 36, 37 Higher BMI at diagnosis could indicate larger muscle reserves to withstand the catabolic demands of an aggressive tumor and accompanying treatment. Although we had limited power for rarer subtypes, this is consistent with the nonsignificantly protective relation of BMI and breast cancer outcomes among Her2-E cancers in our study, suggesting that BMI does not adequately measure adiposity in the setting of catabolic disease. We note that studies with alternative measures of adiposity, such as waist-to-hip ratio, observed more consistent mortality associations within and across IHC subtypes. 9 Body composition assessment could yield biologically relevant measures of fat and lean mass that predict breast cancer outcomes among women with aggressive subtypes where BMI cannot. This study measured BMI at a single time point, yet changes in weight and body composition over time may have the greatest influence on cancer outcomes. The extent of these changes differs by subtype and BMI at diagnosis: in a large cohort of early stage breast cancer survivors, we previously observed that postdiagnosis weight loss was common (20% of women), was disproportionately experienced by obese women and women with nonluminal subtypes, and was associated with reduced survival. 38 Prediagnosis and postdiagnosis weight changes could explain the null association of obesity with outcomes among women with aggressive subtypes: the normal-weight group might include women who lost weight prediagnosis and migrated down BMI categories, and the obese group might contain women who went on to lose weight after diagnosis.
To our knowledge, this is the largest study to date examining the association of BMI with breast cancer outcomes by PAM50 subtype with adjustment for confounders such as race/ethnicity and disease stage. Furthermore, our long duration of follow-up (up to 19 years) enabled us to observe late recurrences in women with luminal A subtypes. This research contributes new information by examining whether physical activity or comorbidities explain associations between BMI and survival. It is noteworthy that, although the point estimates for the rarer, nonluminal subtypes did not suggest an adverse association of BMI with breast cancer outcomes, we had low power to detect associations within these subtypes. Because of limited sample size, we also did not evaluate associations within subgroups defined by both subtype and menopausal status. Although 72% of women in our study were non-Hispanic white, this cohort had more racial/ethnic diversity than previous studies, enhancing generalizability. In addition, women were recruited from medical centers, reducing confounding by health care access but potentially limiting generalizability to the medically insured. Although weights were self-reported, they correlated well with measured weights among women for whom both were available, overall (n 5 490; r 5 0.98) and within subgroups. In all observational research, unmeasured confounding is possible, eg, weight history before diagnosis could partially explain the association of at-diagnosis obesity and breast cancer outcomes.
Conclusion
For patients with luminal A breast cancer, extreme obesity at diagnosis is associated with increased risk of recurrence and breast cancer death. Future research should seek to understand both the impacts of weight change by subtype on breast cancer outcomes and whether direct measurement of body composition outperforms BMI as a predictor of breast cancer outcomes across different biologic subtypes.
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